行情

VERU

VERU

VERU
NASDAQ

实时行情|Nasdaq Last Sale

3.040
-0.080
-2.56%
已收盘, 16:00 04/07 EDT
开盘
3.180
昨收
3.120
最高
3.200
最低
3.010
成交量
16.70万
成交额
--
52周最高
4.740
52周最低
1.180
市值
1.98亿
市盈率(TTM)
-14.7430
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测VERU价格均价为8.25,最高价位13.00,最低价为6.00。

EPS

VERU 新闻

更多
  • 金融大鳄阿克曼在本周公司报告中宣布增持巴菲特公司
  • 新浪财经综合 · 58分钟前
  • 中概股收盘涨跌不一 爱奇艺遭做空反涨3%
  • 新浪美股 · 1小时前
  • 浑水罗列爱奇艺三大财务欺诈行为 本次指控或难坐实
  • 新浪财经 · 2小时前
  • 遭美机构做空 爱奇艺否认质疑股价收涨3.22%
  • 新浪科技 · 2小时前

所属板块

制药
-0.19%
制药与医学研究
-0.82%

热门股票

代码
价格
涨跌幅

VERU 简况

Veru Inc. is an oncology and urology biopharmaceutical company developing medicines for prostate cancer treatment and prostate cancer supportive care, as well as urology specialty pharmaceuticals. Its oncology drug candidates include VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 1b/2 study for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a Phase II clinical trial for the treatment of hot flashes in men, and VERU-100, which is a gonadotropin-releasing hormone (GnRH) antagonist. Its urology specialty pharmaceutical drug candidate is Tadalafil and Finasteride Combination (TADFIN), which is a tadalafil and finasteride combination oral capsule for the treatment of men with benign prostatic hyperplasia. Its commercial products include the FC2 Female/Internal Condom for prevention of pregnancy and sexually transmitted infections, and PREBOOST wipes for the prevention of premature ejaculation.
展开

微牛提供Veru Inc(NASDAQ-VERU)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的VERU股票新闻,以帮助您做出投资决策。